Cardinal Health exec sells 7,354 shares at ~$236

CARDINAL HEALTH INC (CAH) executive Deborah Weitzman, CEO of the Pharmaceutical and Specialty Solutions (PSS) segment, reported selling a total of 7,354 Common Shares on August 18, 2026 in three open-market transactions.

Rhea-AI Filing Summary

CARDINAL HEALTH INC (CAH) executive Deborah Weitzman, CEO of the Pharmaceutical and Specialty Solutions (PSS) segment, reported selling a total of 7,354 Common Shares on August 18, 2026 in three open-market transactions. The sales covered 6,665 shares at a weighted average price of $235.30 (price range $235.17–$236.02), 408 shares at a weighted average price of $236.59 (range $236.24–$237.143), and 281 shares at a weighted average price of $237.44 (range $237.2615–$237.6285). All holdings are reported as directly owned.

Insider Trade Summary

Net Seller: 7,354 shares

Net Sell 3 txns

Insider WEITZMAN DEBORAH

Role CEO, PSS Segment

Sold 7,354 shs ($1.73M)

Type	Security	Shares	Price	Value
Sale	Common Shares F1	6,665	$235.30	$1.57M
Sale	Common Shares F2	408	$236.59	$97K
Sale	Common Shares F3	281	$237.44	$67K

Holdings After Transaction: Common Shares — 77,901 shares (Direct)

Footnotes (3)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.17 to $236.02, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1, 2, and 3 to this Form 4.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.24 to $237.143, inclusive.
3. F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.2615 to $237.6285, inclusive.

Key Figures

First tranche shares sold: 6,665 Common Shares First tranche weighted average price: $235.30 per share Second tranche shares sold: 408 Common Shares +4 more

7 metrics

First tranche shares sold 6,665 Common Shares Sale on August 18, 2026 at weighted average price with range $235.17–$236.02

First tranche weighted average price $235.30 per share Weighted average sale price for 6,665 shares on August 18, 2026 (range $235.17–$236.02)

Second tranche shares sold 408 Common Shares Sale on August 18, 2026 at weighted average price with range $236.24–$237.143

Second tranche weighted average price $236.59 per share Weighted average sale price for 408 shares on August 18, 2026

Third tranche shares sold 281 Common Shares Sale on August 18, 2026 at weighted average price with range $237.2615–$237.6285

Third tranche weighted average price $237.44 per share Weighted average sale price for 281 shares on August 18, 2026

Total shares sold 7,354 Common Shares Aggregate of all reported sales per transactionSummary on August 18, 2026

Key Terms

weighted average price, open market or private transaction, Common Shares

3 terms

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

Common Shares financial

"security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CAH executive Deborah Weitzman report?

Deborah Weitzman reported selling 7,354 Common Shares of Cardinal Health (CAH) on August 18, 2026. The sales occurred in three open-market tranches at weighted average prices between $235.30 and $237.44, each reflecting multiple trades within stated price ranges.

At what prices were Deborah Weitzman’s CAH shares sold?

The reported sales used weighted average prices of $235.30, $236.59, and $237.44 per share. Footnotes state each average reflects multiple transactions within price ranges from $235.17 up to $237.6285 during August 18, 2026 trading.

How many Cardinal Health (CAH) shares did Deborah Weitzman sell in each tranche?

Deborah Weitzman sold 6,665 shares, 408 shares, and 281 shares of CAH Common Shares, all on August 18, 2026. Each tranche was reported as a sale in open market or private transactions at different weighted average prices with specified trading ranges.

Were Deborah Weitzman’s CAH insider sales made in open-market transactions?

Yes. Each transaction is coded “S,” described as a sale in open market or private transaction. The filing notes that prices are weighted averages based on multiple trades within disclosed ranges for each of the three reported tranches on August 18, 2026.

Does the filing show how many CAH shares Deborah Weitzman owns after these sales?

The Form 4 reports these as directly owned sales but does not provide a post-transaction share balance in the structured data. Only the transaction-level share amounts and weighted average sale prices, with their respective trading ranges, are disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 07:30 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEITZMAN DEBORAH

(Last) (First) (Middle)

7000 CARDINAL PLACE

(Street)

DUBLIN OHIO 43017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PSS Segment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/18/2026		S		6,665	D	$235.3(1)	78,590	D
Common Shares	08/18/2026		S		408	D	$236.59(2)	78,182	D
Common Shares	08/18/2026		S		281	D	$237.44(3)	77,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.17 to $236.02, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1, 2, and 3 to this Form 4.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.24 to $237.143, inclusive.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.2615 to $237.6285, inclusive.

Remarks:

	/s/ Amanda S. Pashi, Attorney-in-fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)